CLASS ACTION NOTICE: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors to Inquire About a Securities Fraud Class Action

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for misleading investors regarding its dividend policy following a significant acquisition [1][3]. Company Overview - Organon & Co. is a healthcare company based in Jersey City, NJ, focusing on women's health [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Financial Developments - Following the Dermavant acquisition, Organon increased its debt but assured investors that maintaining its dividend was a top priority [3]. - On May 1, 2025, Organon announced a drastic reduction in its dividend payout from $0.28 per share to $0.02 per share, indicating a shift in capital allocation priorities towards deleveraging [3]. - This announcement led to a significant decline in Organon's stock price, dropping approximately 27% from $12.93 to $9.45 per share [3].